# Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

> **NCT07371104** · PHASE1 · RECRUITING · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 40 (estimated)

## Conditions studied

- Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** DWZ2501 (Olaparib 150mg)
- **DRUG:** DWC202510 (Olaparib 150mg)

## Key facts

- **NCT ID:** NCT07371104
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-22
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07371104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07371104, "Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07371104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*